Feature | Coronavirus (COVID-19) | April 07, 2020 | Dave Fornell, Editor

FDA Approves ECMO to Treat COVID-19 Patients

An ECMO cannula being inserted into a cardiovascular patient in need of mechanical oxygenation and hemodynamic support in December 2019. The FDA just made a temporary approval to use ECMO support in COVID-19 patients during the pandemic emergency. #COVID19 #SARScov2 #coronavirus

An ECMO cannula being inserted into a cardiovascular patient in need of mechanical oxygenation and hemodynamic support at Tufts Medical Center in December 2019. The FDA just made a temporary approval to use ECMO support in COVID-19 patients during the pandemic emergency. Photo by Dave Fornell.

 


April 7, 2020 — The U.S. Food and Drug Administration (FDA) has issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19, SARS-CoV-2) public health emergency.

ECMO systems are used for long-term respiratory/cardiopulmonary failure and provide assisted extracorporeal circulation and physiologic gas exchange of the patient’s blood for more than six hours. The technology can oxygenate a severely sick COVID-19 pneumonia patient's blood without the need to transfer the oxygen through fluid filled lungs.

As a sudden acute respiratory syndrome, COVID-19 can trigger acute respiratory failure and/or acute cardiopulmonary failure. Under these conditions, the FDA states in the new policy extracorporeal oxygenation can now be used for greater than six hours as tool for treating patients. The FDA said it recognizes the importance and utility of increased availability of ECMO devices for patients during the COVID-19 emergency. 

The FDA included a list all the devices that it identified as being technologically capable of being used for ECMO therapy that can now be used for COVID-19 patients.

The FDA also states in the document it does not intend to object to limited modifications to the indications and design of FDA-cleared or FDA-approved ECMO devices and cardiopulmonary bypass devices listed during the declared public health emergency. As long as any modifications do not create an undue risk

As a general best practice, because cardiopulmonary bypass circuit systems might incorporate multiple components, it is recommended that compatibility between components (such as flow rates, coatings, intended patient population) should be considered prior to configuring the circuit for clinical use, the FDA recommends. This includes modifications to cardiopulmonary bypass devices and ECMO devices, such as dimension of cannulae, tubing, filters, connectors, or other accessories to support use in an ECMO circuit that do not affect the flow rate of blood throughout the circuit.

This policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19 declared by the Department of Health and Human Services (HHS). This period will include any renewals made by the HHS secretary.

The FDA included notice of this policy chang in the document "Enforcement Policy for Extracorporeal Membrane Oxygenation and Cardiopulmonary Bypass Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency."

Download the complete ECMO document from the FDA.

 

Related ECMO Use in COVID-19 Content:

FDA Approves ECMO to Treat COVID-19 Patients

VIDEO: ECMO Support Effective in Sickest COVID-19 Patients — Interview with Ryan Barbaro, M.D.

ECMO Used to Treat Adult Respiratory Distress Syndrome Case

ECMO Support Found Effective in Sickest of COVID-19 Patients

LivaNova Modifies its ECMO Indications Beyond Six Hours to Address COVID-19

VIDEO: Multiple Cardiovascular Presentations of COVID-19 in New York — Interview with Justin Fried, M.D., explaining a case that used VV-ECMO abnd VAV-ECMO

New York City Physicians Note Multiple Cardiovascular Presentations of COVID-19

 

Related Cardiology Related COVID-19 Content:

VIDEO: Cancelling Non-essential Cardiac Procedures During the COVID-19 Outbreak — Interview with Ehtisham Mahmud, M.D.

ACC COVID-19 recommendations for the cardiovascular care team

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

The Cardiac Implications of Novel Coronavirus

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Radiologists Describe Coronavirus CT Imaging Features

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

 

Additional COVID-19 Resources for Clinicians:

   ACC COVID-19 Hub page   

   Johns Hopkins Coronavirus Resource Center with inteavtive map of cases in U.S. and worldwide 

   World Health Organization (WHO) COVID-19 situation reports

   World Health Organization (WHO) coronavirus information page

   U.S. Food and Drug Administration (FDA) COVID-19 information page

   Centers for Disease Control (CDC) COVID-19 information page

   Centers for Medicare and Medicaid Services (CMS) frequently asked questions and answers (FAQs) for healthcare providers regarding COVID-19 related payments
 

 

 

Related Content

Feature | Cardiovascular Surgery

The global vascular graft market size was valued at $4,993.64 million in 2020, and is projected to reach $8,138.68 ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

June 14, 2022 — The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

Home April 29, 2022
Home
News | Cardiovascular Surgery
January 18, 2022 – Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has ...
Home February 18, 2022
Home
News | Cardiovascular Surgery
February 15, 2022 – A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA ...
Home February 15, 2022
Home
News | Cardiovascular Surgery

February 11, 2022 — Riverside Community Hospital has earned a distinguished three-star rating from The Society of ...

Home February 11, 2022
Home
News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Subscribe Now